CD123 Antibodies

Gene Name: CD123 (Cluster of Differentiation 123)

Function: CD123, also known as interleukin-3 receptor alpha chain (IL-3Rα), is a cell surface protein that serves as a subunit of the interleukin-3 receptor complex. It is primarily expressed on hematopoietic stem cells and progenitor cells, as well as on certain immune cell subsets, including dendritic cells and basophils. CD123 plays a crucial role in hematopoiesis, immune cell development, and immune responses.

Immune Regulation: CD123 is involved in regulating immune cell development and function, particularly in the context of myeloid cell differentiation and dendritic cell maturation. It serves as a receptor for interleukin-3 (IL-3), a cytokine that regulates the proliferation, survival, and differentiation of hematopoietic cells. CD123 signaling influences the development and activation of myeloid lineage cells and contributes to immune responses against pathogens and antigens.

Apoptosis: While CD123 itself does not directly induce apoptosis, dysregulation of CD123 signaling can affect hematopoietic cell survival and contribute to the pathogenesis of certain hematological malignancies. Aberrant CD123 expression or activation has been observed in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and other hematopoietic disorders, suggesting a potential role in apoptosis regulation in these diseases.

Research Implications: Understanding the functions of CD123 is important for elucidating its roles in hematopoiesis, immune regulation, and hematological diseases. Research on CD123 signaling pathways may have implications for the development of therapies targeting hematopoietic-related diseases and immune disorders.

Clinical Relevance: CD123 has emerged as a therapeutic target for the treatment of hematological malignancies, particularly AML and ALL. Monoclonal antibodies targeting CD123, such as tagraxofusp (SL-401) and flotetuzumab, have been developed for the treatment of CD123-positive leukemias. Additionally, CD123-directed CAR-T cell therapies are being investigated for the treatment of CD123-positive AML and ALL.